0001839285
false
0001839285
2023-07-13
2023-07-13
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
Form
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of The Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported) July 13,
2023
HEALTHCARE
TRIANGLE, INC.
(Exact
name of registrant as specified in its charter)
Delaware |
|
001-40903 |
|
84-3559776 |
(State
or other jurisdiction of incorporation) |
|
(Commission
File Number) |
|
(IRS
Employer Identification No.) |
7901
Stoneridge Dr., Suite
220 Pleasanton, CA
94588
(Address
of principal executive offices)
(925)-270-4812
(Registrant’s
telephone number, including area code)
N/A
(Former
name or former address, if changed since last report.)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions:
☐
Written communications pursuant to Rule 425 under the
Securities Act (17 CFR 230.425)
☐
Soliciting material pursuant to Rule 14a-12 under the
Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement communications pursuant to Rule 13e-4(c)
under the Exchange Act (17 CFR 240.13e-4(c))
Securities
registered pursuant to Section 12(b) of the Act:
Title
of each class |
|
Trading
Symbol(s) |
|
Name
of each exchange
on which registered |
Common
Stock, par value $0.00001 per share |
|
HCTI |
|
The
Nasdaq Stock Market LLC |
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ☒
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On July 13, 2023, Healthcare Triangle Inc. (the
“Company”) entered into a revised board agreement with Mr. Dave Rosa, Chairman of the Board of Directors of the Company
(the “Agreement”), effective July 1, 2023. Mr. Rosa qualifies as an ‘independent director’ for purposes
of the NASDAQ listing standards, and apart from being the Chairman of the Board, serves as Chairman of the Compensation Committee and
as a member on the Company’s Audit Committee.
Mr. Rosa has served as a member of our board of
directors since August 2021. Since 2016, Mr. Rosa has been and currently is President and CEO of NeuroOne Medical Technologies (NMTC:
Nasdaq), a publicly traded company on the Nasdaq. He also serves on the boards of Biotricity (BTCY: OTC), a publicly traded company on
the Over the Counter (OTC) platform, where he currently serves as compensation committee chairman and Neuro Event Labs, a privately held
company in Finland, where he currently serves as Chairman of the Board. Mr. Rosa has over 25 years of experience holding a variety of
senior management roles representing several medical device markets. His recent experience includes developing early-stage companies to
commercialization and Nasdaq listing. Mr. Rosa holds a Master of Business Administration degree from Duquesne University and Bachelor
of Science degree in Commerce and Engineering from Drexel University.
Per the revised Agreement, Mr. Rosa will receive
compensation consistent with his expanded duties and critical service to the Company. Mr. Rosa’s compensation, per the Agreement
Mr. Rosa shall comprise of (i) an annual cash stipend of $120,000, and (b) an annual grant of stock options for 10,000 shares of the Company’s
common stock under its 2020 Stock Incentive Plan.
Among his key responsibilities as Chairman of
the Board, Mr. Rosa will ensure compliance with corporate governance standards applicable to the Company, chair meetings of the Company’s
Board, shareholders and executive sessions of the Board, coordinate the activities of the directors of the Board, serve as a formal liaison
between the Company’s senior management and the directors of the Board, coordinate the activities of the Board’s operating
committees and assist management in maintaining effective communication with the Company’s shareholders. The Agreement may be terminated
by Mr. Rosa immediately by notice in writing.
There are no family relationships between Mr.
Rosa and any of the Company’s directors or executive officers and he has no direct or indirect material interest in any transaction
required to be disclosed pursuant to Item 404(a) of Regulation S-K.
The above description is a summary of the Agreement and does not purport to be complete
and is subject to, and is qualified in its entirety by reference to, the full text of the Agreement, which is filed as Exhibit 10.1,
respectively, with this Current Report on Form 8-K and are incorporated herein by reference.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
|
Healthcare
Triangle, Inc. |
|
|
Date:
July 14, 2023 |
By:
/s/ Thyagarajan Ramachandran |
|
Name:
Thyagarajan Ramachandran |
|
Title:
Chief Financial Officer |
Dave Rosa
9705 Emerson Court
Eden Prairie, MN 55347
July 13, 2023
RE: Healthcare Triangle, Inc.’s Board of Directors
- Board Agreement
Dear Dave:
The Compensation Committee
and the Board of Directors (the “Board”) of Healthcare Triangle, Inc. (the “Company”) has unanimously consented
to revise the Board fees effective July 01, 2023.
1. Your Duties:
a)
You will be expected to attend (either in person or by teleconference) all regular meetings of the Board, of which we expect to
hold approximately four to six per annum, as well as to attend (either in person or by teleconference), if feasible, any special meetings
of the Board and to sign all written consents if you deem appropriate. In addition, you will be expected to perform such other duties
as are reasonably contemplated by your holding office as a director of the Company or which may reasonably be assigned to you by the Board
from time to time, including Committee(s) membership.
b)
As a director you will at all times act as a fiduciary in the service of the best interests of the Company. In addition, you agree
to (i) provide all information regarding yourself as the Company requires to satisfy its disclosure obligations under applicable securities
laws; and (ii) timely file with the Securities and Exchange Commission all reports and schedules required of you in your personal capacity
by virtue of your relationship with the Company (e.g., Forms 3, 4 and 5 as contemplated by Section 16(a) of the Securities Exchange Act
of 1934).
c)
As you will appreciate, your time commitment will ultimately be a function of the matters confronting the Company from time to
time and matters properly requiring your attention as a director of the Company.
d)
You shall comply with all the fiduciary-duty obligations of a director as imposed by Delaware law. Subject to your fiduciary-duty
obligations as a director as imposed by Delaware law, this Letter does not otherwise restrict you from accepting appointment as a director
of any other company, providing consulting services, becoming employed by or engaging in any other business or other activity whatsoever.
2. Remuneration:
a)
Cash: You will receive an annual cash stipend of $120,000. Cash stipend of $40,000 for being a Board member, $60,000 for
being the Chairman of the Board and $20,000 for being Chairman of the Compensation Committee, payable on the first day of each calendar
quarter, for your service on the Board.
b)
Annual Options: The Company expects to provide you for service on the Board, an annual grant of stock options for 10,000 shares
of the Company’s common stock on the date of grant under our 2020 Stock Incentive Plan (Plan). Such stock options shall remain exercisable
until the earlier of the 5 years from the date of grant or 18 months after the cessation of service, whichever is sooner.
c)
Expenses: Subject to you providing the Company with receipts or other evidence of payment, the Company will pay for or reimburse
you for all travelling, hotel and other expenses reasonably incurred by you in connection with attending and returning from Board or Committee
meetings or otherwise in connection with the Company's business. “Reasonable” air travel expenses assume economy class for
flights under 4 hours and business class for flights over 4 hours.
3. Termination of Director Status:
a)
Your status as a director may be terminated at any time by the vote of the stockholders of the Company (including any failure to
elect you for an ensuing term at any annual meeting of stockholders) in accordance with the certificate of incorporation and bylaws of
the Company. Any such termination will not affect your rights under options that have become vested, subject to the post-service exercisability
period.
b)
You acknowledge and agree that if the stockholders of the Company terminate your status as a Director (including any failure to
elect you for an ensuing term at any annual meeting of stockholders), you will have no claim of any kind against the Company by reason
of the termination.
c)
You are at liberty to resign from the Board at any time by notice in writing to the Company.
4. What happens after termination of Director Status?
If your Director status is terminated for any reason or you
resign for any reason:
a)
The Company may set off any amounts you owe the Company against any amounts the Company owes to you as a Director at the date of
termination except for amounts the Company is not entitled by law to set off;
b)
You must return all the Company's property (including property leased by the Company) to the Company on termination including all
written or machine-readable material, software, computers, credit cards, keys and vehicles; and
c)
You shall return to the Company all confidential information and documentation (including any copies thereof) regarding the Company
and its affiliates (including confidential information of third parties entrusted to the Company) within 5 business days following the
Company's request and to delete or destroy any electronic or written information relating to the Company, as shall be requested by the
Company.
5. Confidential Information:
a)
You acknowledge and agree that during your service with the Company, you will receive confidential information regarding the Company
and its affiliates (including confidential information of third parties entrusted to the Company) and that you will not disclose any such
information to any other party nor use for your own benefit or for the benefit of any third person any of the confidential information
so obtained at any time during or after the term of your service with the Company without the Company's prior written consent.
b)
You recognize and affirm that in the event of your breach of any provision of this Section 5, monetary damages would be inadequate,
and the Company and its subsidiaries would have no adequate remedy at law. Accordingly, you agree that in the event of a breach or threatened
breach by you of the provisions of this Section 5, the Company, in addition and supplementary to any other rights and remedies existing
in its favor, may apply to any court of law or equity of competent jurisdiction for specific performance and/or injunctive or other relief
in order to enforce or prevent any violations of the provisions hereof (without posting a bond or other security).
6. Protection:
a)
During the term of your engagement hereunder, the Company will use reasonable commercial efforts to procure and maintain directors'
and officers' liability insurance policies with a minimum of $5,000,000 Aggregate Limit, and to ensure that you are included as an insured
thereunder.
b)
The Company will enter into a standard and customary Indemnification Agreement with you on terms reasonably acceptable to you which
will provide for (i) your indemnification by the Company to the fullest extent permitted by law for all acts and/or omissions directly
and/or indirectly related to any services provided by you to the Company and (ii) the advancement of your expenses in the event any action
and/or investigation is commenced regarding any acts and/or omissions directly and/or indirectly related to any services provided by you
to the Company.
7. Miscellaneous
a) Alterations: This Letter cannot be amended except in a writing signed by each party.
b)
Entire Agreement: This Letter constitutes the entire agreement between the parties in connection with its subject matter and supersedes
all previous agreements or understandings between the parties in connection with its subject matter.
c)
Further Action: Each party must do, at its own expense, everything reasonably necessary (including executing documents) to give
full effect to the performance of his/its obligations under this Letter and the transactions contemplated by it.
d)
Waiver: A party does not waive a right, power, or remedy (or any other right, power or remedy) if it fails to exercise or delays
in exercising the right, power or remedy. A single or partial exercise of a right, power or remedy does not prevent another or further
exercise of that or another right, power or remedy. A waiver of a right, power or remedy must be in writing and signed by the party giving
the waiver.
e)
Relationship: This Letter does not create a relationship of employment, agency, or partnership between the parties. Unless the
Board adopts a specific resolution so providing, you do not have authority to bind the Company to any contract or commitment; and you
agree not to purport to do so.
f)
Governing Law: This Letter shall be governed by and construed in accordance with the laws of Delaware (without giving effect to
choose of law principles or rules thereof that would cause the application of the laws of any jurisdiction other than Delaware).
g)
Severability: Any provision of this Letter, which is prohibited or unenforceable in any jurisdiction shall, as to such jurisdiction,
be ineffective only to the extent of such prohibition or unenforceability without invalidating or affecting the remaining provisions hereof,
and any such prohibition or unenforceability in any jurisdiction shall not invalidate or render unenforceable such provision in any other
jurisdiction.
h)
Counterparts: This Letter may be executed in counterparts. All executed counterparts constitute one document.
[REMAINING PAGE INTENTIONALLY LEFT BLANK]
[SIGNATURE PAGES BELOW]
Please sign and return the attached copy
of this Letter to indicate that you have read, have understood and accept the terms of your appointment.
|
|
Very truly yours, |
|
|
|
|
|
Healthcare Triangle, Inc. |
|
|
|
|
|
|
|
|
By:_______________________ |
|
|
Name: Thyagarajan Ramachandran |
|
|
Title: Chief Financial
Officer |
|
|
|
Agreed to and accepted by: |
|
|
|
|
|
|
|
|
Dave Rosa |
|
|
v3.23.2
X |
- DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission.
+ References
+ Details
Name: |
dei_AmendmentFlag |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.
+ References
+ Details
Name: |
dei_DocumentPeriodEndDate |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:dateItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
+ References
+ Details
Name: |
dei_DocumentType |
Namespace Prefix: |
dei_ |
Data Type: |
dei:submissionTypeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAddress Line 1 such as Attn, Building Name, Street Name
+ References
+ Details
Name: |
dei_EntityAddressAddressLine1 |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Definition
+ References
+ Details
Name: |
dei_EntityAddressCityOrTown |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCode for the postal or zip code
+ References
+ Details
Name: |
dei_EntityAddressPostalZipCode |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the state or province.
+ References
+ Details
Name: |
dei_EntityAddressStateOrProvince |
Namespace Prefix: |
dei_ |
Data Type: |
dei:stateOrProvinceItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityCentralIndexKey |
Namespace Prefix: |
dei_ |
Data Type: |
dei:centralIndexKeyItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionIndicate if registrant meets the emerging growth company criteria.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityEmergingGrowthCompany |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.
+ References
+ Details
Name: |
dei_EntityFileNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:fileNumberItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTwo-character EDGAR code representing the state or country of incorporation.
+ References
+ Details
Name: |
dei_EntityIncorporationStateCountryCode |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarStateCountryItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityRegistrantName |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityTaxIdentificationNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:employerIdItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionLocal phone number for entity.
+ References
+ Details
Name: |
dei_LocalPhoneNumber |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 13e -Subsection 4c
+ Details
Name: |
dei_PreCommencementIssuerTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 14d -Subsection 2b
+ Details
Name: |
dei_PreCommencementTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTitle of a 12(b) registered security.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b
+ Details
Name: |
dei_Security12bTitle |
Namespace Prefix: |
dei_ |
Data Type: |
dei:securityTitleItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the Exchange on which a security is registered.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection d1-1
+ Details
Name: |
dei_SecurityExchangeName |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarExchangeCodeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Section 14a -Number 240 -Subsection 12
+ Details
Name: |
dei_SolicitingMaterial |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTrading symbol of an instrument as listed on an exchange.
+ References
+ Details
Name: |
dei_TradingSymbol |
Namespace Prefix: |
dei_ |
Data Type: |
dei:tradingSymbolItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Securities Act -Number 230 -Section 425
+ Details
Name: |
dei_WrittenCommunications |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
Healthcare Triangle (NASDAQ:HCTI)
Gráfica de Acción Histórica
De Abr 2024 a May 2024
Healthcare Triangle (NASDAQ:HCTI)
Gráfica de Acción Histórica
De May 2023 a May 2024